4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists

Qingan Zou, Hongliang Duan, Mengmeng Ning, Jia Liu, Ying Feng, Liming Zhang, Junjie Zhu, Ying Leng, Jianhua Shen

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


A series of 4-benzofuranyloxynicotinamide derivatives were identified to be novel, potent, and orally available TGR5 agonists. Among them, compound 9r had the highest potency in vitro (hTGR5 EC50 = 0.28 nM, mTGR5 EC 50 = 0.92 nM). Further in vivo studies disclosed that 9r could effectively lower the blood glucose, but meantime caused an increase in the gallbladder volume of mice. Subsequent research toward eliminating the gallbladder toxicity resulted in compound 19 with low permeability. Although the EC50 of mTGR5 of 19 was larger one order than that of 9r, it still had good glucose-lowing activity. Nevertheless, 19 also caused the adverse effects to the gallbladder. The drug levels detection disclosed that the concentration of 19 was only lower than that of 9r in plasma but was higher in bile and gallbladder tissue. This result indicated that low exposure in plasma could not guarantee low exposure in bile and gallbladder tissue, and thus resulting in the gallbladder toxicity of 19.

Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalEuropean Journal of Medicinal Chemistry
Publication statusPublished - 23 Jul 2014
Externally publishedYes


  • 4-Benzofuranyloxynicotinamide
  • Caco-2 permeability
  • Gallbladder toxicity
  • TGR5


Dive into the research topics of '4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists'. Together they form a unique fingerprint.

Cite this